One dose of intravenous antibiotics for complicated urinary tract infections in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicentre, open-label, non-inferiority randomized controlled trial aims to compare the effectiveness of a single dose of intravenous antibiotics followed by two days of oral antibiotics against the standard three doses of intravenous antibiotics for treating complicated urinary tract infections (cUTIs) in children. The study will enroll children aged 3 months to 18 years presenting to the emergency department with specific complicated features of UTI. The primary outcome will assess symptom resolution at 72 hours post-treatment, while secondary outcomes will evaluate readmission rates due to persistent symptoms. This approach seeks to reduce unnecessary hospital stays and antibiotic exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 3 months (corrected age) to 18 years
* Fever (reported fever at home or measured fever of ≥38 degrees Celsius associated with the illness that triggered current ED presentation (eg fever may have been 18 hours prior to presentation but none since then because patient has been on maximal antipyretics - paracetamol or ibuprofen)
* Any of the following complicating features: Vomiting, Rigors, History of recurrent UTI, Urological abnormalities, Tachycardia
* Urine sample available (Urine culture must have been collected prior to or within an hour of antibiotic treatment, either at the GP or ED - in order to assess urine culture as per below).
* Abnormal urinary dipstick leucocyte esterase \>1+ or nitrite positive OR ≥5 White Blood Cells (WBCs) per high-power field in centrifuged urine OR≥ 10 White Blood Cells (WBCs) per mm3 in uncentrifuged urine and bacteriuria with any bacteria per high-power field
* ED clinician determines the child requires treatment with IV antibiotics \* In ED, only urine dipstick or urinalysis will be available. Once urine culture is available, to be included in the efficacy analysis, culture results must meet the following criteria: Positive urine culture result with no more than 2 species of microorganisms AND Spontaneously voided urine with ≥105 microorganisms per mL of urine or Suprapubic aspirate or urinary catheter with ≥104 microorganisms per mL of urine. In the absence of a positive urine culture, ultrasonographic findings supporting pyelonephritis (per reporting radiologist) will be accepted as evidence of a urinary tract infection. In the absence of a positive urine culture or supportive ultrasonographic findings, a case will also be accepted as presumed UTI where the treating clinician has provided a diagnosis of UTI and treated the patient accordingly.

Exclusion Criteria:

* Sepsis (requiring inotropic support or more than 20ml/kg of fluid bolus in Emergency Department)
* Known allergy to all once daily study drug options (gentamicin or ceftriaxone or amikacin)
* If the patient has another co-existing condition which requires (based on established evidence-based guidelines) more than 1 dose of IV antibiotics eg meningitis
* Known chronic renal failure or renal transplant patients
* Unrepaired posterior urethral valves
* Indwelling stent and fever
* Previously enrolled participants in the CHOICE UTI trial.
* No available oral antibiotic option for this UTI: urine culture result already available and multi-resistant organism with susceptibility only to IV antibiotics or known intolerance to oral antibiotics (previous UTI with multi-resistant organism not an exclusion)
* Previous IV antibiotics for same UTI episode eg interhospital transfer whereby significant time has passed since first dose IV
* Patients with clinically suspected renal abscess e.g., extreme renal tenderness, out of keeping with pyelonephritis (clinically determined).
* Clinician does not intend on prescribing a course of IV antibiotics but plans on only giving a single dose from the outset
* Recurrence of urinary tract infection within 2 weeks
* Unable to obtain consent
* Patient is pregnant

Where it's running

• Flinders Medical Centre
  Adelaide, South Australia, Australia Recruiting
• Women and Children's Hospital
  Adelaide, South Australia, Australia Recruiting
• University Hospital Geelong
  Geelong, Victoria, Australia Recruiting
• Monash Health
  Melbourne, Victoria, Australia Recruiting
• Royal Children's Hospital
  Parkville, Victoria, Australia Recruiting
• Perth Children's Hospital
  Perth, Washington, Australia Recruiting

Study contacts

• Principal investigator: Laila Ibrahim — Murdoch Childrens Research Institute
• Study coordinator: Laila Ibrahim
• Email: laila.ibrahim@mcri.edu.au
• Phone: +61401765546

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reducing unnecessary antibiotic use for children with ear infections

  This study is testing two different ways to help doctors give fewer unnecessary antibiotics to kids with ear infections to see which one makes parents happier and follows health guidelines better.

  Recruiting at 3 sites Intermountain Health Care, Inc. · Denver, Colorado and 2 other locations · NCT06034080

• Investigating cefepime-enmetazobactam for treating complicated urinary tract infections in children

  This study is testing a new combination of antibiotics to see if it can safely and effectively treat complicated urinary tract infections in children who are in the hospital.

  Recruiting at 4 sites Phase 2 Orchid Pharma Europe GmbH · Hradec Králové and 7 other locations · NCT05826990

• Learning about the safety and effectiveness of Zavicefta in Korea

  This study is trying to learn how safe and effective Zavicefta is for treating serious infections in both adults and kids in Korea after it has been released for use.

  Recruiting Pfizer · Seoul, Gangnam-gu · NCT05733104

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

• Optimizing HIV Therapy for AIDS-Related Lymphoma Patients

  This study tests whether long-acting HIV medicines given during lymphoma treatment work better at keeping the virus suppressed than standard oral therapy in adults with AIDS-related lymphoma.

  Recruiting Shanghai Public Health Clinical Center · Shanghai, Shanghai Municipality · NCT07727642

• Colchicine to see if it reduces coronary artery inflammation in people with HIV

  This study tests whether low-dose colchicine can lower inflammation in the coronary arteries of people with HIV who are at high heart-disease risk, compared with a placebo.

  Recruiting at 2 sites Phase 2 Instituto de Investigación Hospital Universitario La Paz · Barcelona and 3 other locations · NCT07704164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.